Improved Treatment for Patients With Long-term Opioid Therapy for Non-cancer Pain in Primary Care

NCT ID: NCT06856733

Last Updated: 2025-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-10

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:

What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?

Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.

Participants will receive a person-centred team-based treatment consisting of:

* Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
* Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
* Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.

Primary objective:

To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care

Trial design and setting:

This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).

This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.

Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Pain Chronic Pain Management Primary Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care.

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention

Phase 1 (investigation and assessment, week 1-3):

* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
* A visit to a care manager

Phase 2 (treatment plan, week 3-4):

\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

* Implementation of the individualized rehabilitation plan.
* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
* A second team consultation half-way

Group Type ACTIVE_COMPARATOR

Person-centred team-based approach

Intervention Type BEHAVIORAL

Phase 1 (investigation and assessment, week 1-3):

* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
* A visit to a care manager

Phase 2 (treatment plan, week 3-4):

\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

* Implementation of the individualized rehabilitation plan.
* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
* A second team consultation half-way

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Person-centred team-based approach

Phase 1 (investigation and assessment, week 1-3):

* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.
* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.
* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.
* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.
* A visit to a care manager

Phase 2 (treatment plan, week 3-4):

\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.

Phase 3 (treatment and follow-up, week 4-24):

* Implementation of the individualized rehabilitation plan.
* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.
* A second team consultation half-way

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
* Able to speak Swedish or English

Exclusion Criteria

* Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
* No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents informed consent.
* Using their opioids for cancer pain
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Uppsala University

OTHER

Sponsor Role collaborator

Uppsala County Council, Sweden

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Thomas Kempen

Assistant professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Region Uppsala

Uppsala, , Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Magnus Peterson, PhD, MD

Role: CONTACT

+46702882768

Anna Svensson, MD

Role: CONTACT

+46702206400

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anna Svensson

Role: primary

+46702206400

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Opi-Prim

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Reducing the Abuse of Opioids in Drug Users
NCT03837860 TERMINATED EARLY_PHASE1